Taft, one of the fastest-growing law firms in the nation, is pleased to welcome Michael Nutter in the Pharmaceutical and Life Sciences Litigation practice in Chicago. Prior to joining Taft, Nutter was partner and chair of the Pharmaceutical and Life Sciences Patent Litigation group at a leading Am Law 100 firm.

Nutter is a first-chair trial lawyer and registered patent attorney who focuses on small-molecule pharmaceutical patent litigation within the framework of the Hatch Waxman Act and biosimilar patent litigation within the Biologics Price Competition and Innovation Act (BPCIA). The depth of his experience in this space has been recognized by IAM Patent 1000, which notes that he is a “star of the pharmaceutical circuit.”

Nutter’s clients are primarily generic drug companies facing patent infringement cases involving Abbreviated New Drug Applications (ANDAs) that include a Paragraph IV certification to one or more Orange Book-listed patents. He works closely with his clients to resolve ANDA-related issues before the FDA, including labeling issues, issues with API, patent listing disputes, and issues pertaining to new drug and marketing exclusivities.